ArticleLipids in health and disease2025
The polyunsaturated-to-monounsaturated fatty acid ratio and cardiovascular risk prediction: a prospective cohort study of 183,237 adults.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasma fatty acid composition modifies the cardiovascular risk of long-term PMLipids in health and disease · 2026Article
- Metabolomic profiling refines cardiovascular risk stratification beyond SCORE2-diabetes in patients with concurrent type 2 diabetes and pulmonary dysfunction.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImproving the accuracy of 10-year cardiovascular risk prediction beyond established algorithms like SCORE2 is a clinical priority. The plasma ratio of polyunsaturated to monounsaturated fatty acids (PUFA/MUFA) is an objective marker of dietary fat quality, which is linked to cardiovascular health. This study aimed to evaluate whether adding the PUFA/MUFA ratio to the SCORE2 model improves the prediction of major adverse cardiovascular events (MACE).
methodsThis prospective cohort study included 183,237 UK Biobank participants aged 50–69 years, free of cardiovascular disease or diabetes at baseline. The plasma PUFA/MUFA ratio was quantified using high-throughput nuclear magnetic resonance (NMR) spectroscopy. The cohort was randomly split into training (70%) and validation (30%) sets. The predictive performance of the original SCORE2 model was compared to an extended model including the PUFA/MUFA ratio, using Harrell’s C-index, Net Reclassification Improvement (NRI), and Integrated Discrimination Improvement (IDI).
resultsIn the independent validation set (N = 54,971), a higher PUFA/MUFA ratio was associated with a lower risk of MACE. Adding the PUFA/MUFA ratio to the SCORE2 model resulted in a statistically significant increase in the C-index from 0.740 (95% CI: 0.736–0.743) to 0.744 (95% CI: 0.740–0.748) (P < 0.001). The extended model also showed significant risk reclassification, with An NRI of 7.5% (95% CI: 3.5–11.4%) And An IDI of 0.025 (95% CI: 0.016–0.034). Both models were well-calibrated.
conclusionsIncorporating the plasma PUFA/MUFA ratio into the SCORE2 algorithm provides a modest but statistically significant improvement in 10-year MACE risk prediction. As an objective biomarker of dietary fat quality, the PUFA/MUFA ratio shows promise as a supplementary tool for risk assessment, though its direct clinical impact requires further validation and consideration of cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.